Plasma Lipoprotein Changes Induced by Diets and Drugs

  • Cesare R. Sirtori
Conference paper
Part of the NATO Advanced Study Institutes Series book series (NSSA, volume 51)


Diet and/or drugs are commonly used for the management of hyperlipoproteinemias (1). On the other hand diets and, at times, drugs are also prescribed to normolipidemic individuals, in the hope of modifying risk factors for Atherosclerosis. Among these, low high density lipoprotein (HDL) cholesterol levels (2), obesity (3), hypertension (4) and increased platelet aggregation (5) are often managed by diet and drug treatments which may modify plasma lipid transport.


Bile Acid High Density Lipoprotein Nicotinic Acid Plasma Free Fatty Acid Plasma High Density Lipoprotein 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    C.R. Sirtori, G.C. Ghiselli, and M.R. Lovati, Dietary effects on lipoprotein composition, in: “The Lipoprotein Molecule”, H. Peeters, ed., NATO Adv. Study Inst., Plenum Press, New York, p. 261 (1978).Google Scholar
  2. 2.
    G.J. Miller and N.E. Miller, Plasma high density lipoprotein concentration and development of Atherosclerosis, Lancet i: 16 (1978).Google Scholar
  3. 3.
    F.W. Ashley jr. and W.B. Kannel, Relation of weight changes to changes in atherogenic traits: The Framingham Study, J. Chron. Pis. 27: 103 (1974).CrossRefGoogle Scholar
  4. 4.
    J. Stamler, R. Stamler, W.F. Riedlinger, etal., Hypertension screening of 1 million Americans, J. Am. Med. Ass. 235: 2299 (1976).Google Scholar
  5. 5.
    P.C. Elwood and P.M. Sweetman, Aspirin and secondary mortality after myocardial infarction, Lancet ii: 1313 (1979).Google Scholar
  6. 6.
    E. Florence and J. Quarterman, The effects of age, feeding pattern and sucrose on glucose tolerance and plasma free fatty acids and insulin concentrations in the rat, Br. J. Nutr. 28:63 (1972).Google Scholar
  7. 7.
    W.M. Bortz, P. Howat, and W.L. Holmes, The effect of feeding frequency on diurnal plasma free fatty acids and glucose levels, Metabolism 18: 120 (1969).PubMedCrossRefGoogle Scholar
  8. 8.
    R.M. Kay, S. Rao, C. Arnott, etal., Acute effects of fat ingestion on plasma high density lipoprotein components in man, Atherosclerosis 36: 567 (1980).PubMedCrossRefGoogle Scholar
  9. 9.
    D.E. Wilson and R.S. Lees, Metabolic relationships among the plasma lipoproteins: reciprocal changes in the concentrations of very low and low density lipoproteins in man. J. Clin. Invest. 51: 1051 (1972).PubMedCrossRefGoogle Scholar
  10. 10.
    B. Vessby and M. Lithell, Dietary effects on lipoprotein levels in hyperlipoproteinemia. Delineation of two subgroups of endogenous hypertriglyceridemia. Artery 1: 63 (1976).Google Scholar
  11. 11.
    D.S. Goodman, F.R. Smith, A.H. Seplowitz, etal., Prediction of parameters of whole body cholesterol Metabolism in humans. J. Lipid Res. 21:699 (1980).Google Scholar
  12. 12.
    C.G. Schwartz, L.G. Halloran, Z.R. Vlahcevic, etal., Preferential utilization of free cholesterol from high density lipoproteins for biliary cholesterol secretion in man, Science 200: 62 (1978).PubMedCrossRefGoogle Scholar
  13. 13.
    P.J. Nestel and N.E. Miller, Mobilization of adipose tissue cholesterol in high density lipoprotein during weight reduction in man, in “High density Lipoproteins and Ath-erosclerosis”, A.M. Gotto jr., Elsevier/ North Holland, Amsterdam, p. 51 (1978).Google Scholar
  14. 14.
    P.D. Thompson, R.W. Jeffery, R.R. Wing, and P.D. Wood, Unexpected decrease in plasma high density lipoprotein cholesterol with weight loss, Am. J. Clin. Nutr. 32:2016 (1979).Google Scholar
  15. 15.
    S.B. Hulley, R. Cohen, and G. Widdowson, Plasma high-density lipoprotein cholesterol level: influence of risk factor intervention, J. Am. Med. Ass. 238:2269 (1977).Google Scholar
  16. 16.
    F. Contaldo, P. Strazzullo, A. Postiglione, etal., Plasma high density lipoprotein in severe obesity after weight loss, Atherosclerosis 37: 163 (1980).PubMedCrossRefGoogle Scholar
  17. 17.
    D.A. Streja, E. Boyko, and S.W. Rabkin, Changes in plasma high-density lipoprotein cholesterol concentration after weight reduction in grossly obese subjects. Brit. Med. J. 281: 770 (1980).PubMedCrossRefGoogle Scholar
  18. 18.
    J.L. Witztum, M.A. Dillingham, W. Giese, etal., Normalization of triglycerides in type IV hyperlipoproteinemia fails to correct low levels of high-density-lipoprotein cholesterol, N. Eng. J. Med. 303:907 (1980).Google Scholar
  19. 19.
    O. Turpeinen, M.J. Karvonen, M. Pekkarinen, etal., Dietary prevention of coronary heart disease: The Finnish Mental Hospital Study, Int. J. Epidemiol. 8: 99 (1979).PubMedCrossRefGoogle Scholar
  20. 20.
    J.J. Salonen, P. Puska and H. Mustanieni, Changes in morbidity and mortality during comprehensive community programme to control cardiovascular diseases during 1972–73 in North Karelia, Brit. Med. J. 2: 1178 (1979).PubMedCrossRefGoogle Scholar
  21. 21.
    J.V. Joossens, K. Vuylsteek, E. Brems-Heyns, etal., The pattern of food and mortality in Belgium, Lancet i: 1069 (1977).Google Scholar
  22. 22.
    W.E. Connor, D.T. Witiak, D.B. Stone, and M.L. Armstrong, Cholesterol balance and fecal neutral steroid and bile acid excretion in normal men fed dietary fats of different fatty acid composition, J. Clin. Invest. 48: 1363 (1969).PubMedCrossRefGoogle Scholar
  23. 23.
    S.M. Grundy and E.H. Ahrens jr., The effects of unsaturated dietary fats on absorption, excretion, synthesis, and distribution of cholesterol in man, J. Clin. Invest. 49: 1135 (1970).PubMedCrossRefGoogle Scholar
  24. 24.
    R.A.L. Sturdevant, M.L. Pearce, and S. Dayton, Increased prevalence of cholelithiasis in men ingesting a serum- cholesterol-lowering diet, N. Eng. J. Med. 288:24 (1973).Google Scholar
  25. 25.
    A. Chait, A. Onitiri, A. Nicoll, etal., Reduction of serum triglyceride levels by polyunsaturated fat. Studies on the mode of action and on the very low density lipopro-tein composition. Atherosclerosis 20: 347 (1974).PubMedCrossRefGoogle Scholar
  26. 26.
    J. Shepherd, C.J. Packard, J.P. Patsch, etal., Effects of polyunsaturated fat on the properties of high density lipoproteins and the Metabolism of apoprotein A-I, J. Clin. Invest. 61: 528 (1978).CrossRefGoogle Scholar
  27. 27.
    B. Vessby, J. Boberg, I.-B. Gustafsson, etal., Reduction of high density lipoprotein cholesterol and apoprotein A-I concentrations by a lipid-lowering diet, Atherosclerosis 35: 21 (1980).PubMedCrossRefGoogle Scholar
  28. 28.
    R.M. Glickman and P.H.R. Green, The intestine as a source of apoprotein A-I, Proc. Natl. Acad. Sci. U.S.A. 74: 2569 (1977).PubMedCrossRefGoogle Scholar
  29. 29.
    N.A. Spritz and M.A. Mishkel, Effects of dietary fats on plasma lipids and lipoproteins: an hypothesis for the lipid- lowering effect of unsaturated fatty acids, J. Clin. Invest. 48: 78 (1969).PubMedCrossRefGoogle Scholar
  30. 30.
    I. Hjermann, S.C. Enger, A. Helgeland, etal., The effect of dietary changes on high density lipoprotein cholesterol, Am. J. Med. 66:105 (1979).Google Scholar
  31. 31.
    R.L. Jackson, C.J. Glueck, S.N. Mathur, and A.A. Spector, Effects of diet and high density lipoprotein subfractions on the removal of cellular cholesterol, Lipids 15: 230 (1980).PubMedCrossRefGoogle Scholar
  32. 32.
    W.F. Connor, R.E. Hodges, and R.E. Bleiler, The serum lipids in men receiving high cholesterol and cholesterol-free diets. J. Clin. Invest. 40: 894 (1961).PubMedCrossRefGoogle Scholar
  33. 33.
    F.H. Mattson, B.A. Erickson, and A.M. Kligman, Effect of dietary cholesterol in man, Am. J. Clin. Nutr. 25:589 (1972).Google Scholar
  34. 34.
    H.P. Rhomberg and H. Braunsteiner, Excessive egg consumption, xanthomatosis and hypercholesterolemia, Brit. Med. J. 2: 188 (1976).Google Scholar
  35. 35.
    S. Slater, J. Mead, G.A. Dhopeshwarkar, etal., Plasma cholesterol and triglycerides in men with added eggs in the diet, Nutr. Rep Int. 14: 249 (1976).Google Scholar
  36. 36.
    M.W. Porter, W. Yamamaka, S.D. Carlson, and M. A. Flynn, Effect of dietary egg on serum cholesterol and triglyceride of human males, Am. J. Clin. Nutr. 30:490 (1977).Google Scholar
  37. 37.
    M.A. Flynn, G.B. Nolph, T.C. Flynn, etal., Effect of dietary egg on human serum cholesterol and triglycerides, Am. J. Clin. Nutr. 32:1051 (1979).Google Scholar
  38. 38.
    D.C. Bronsgeest-Schoute, J.G.A.J. Hautvast, R.J.J. Hermus, etal., Dependence of the effects of dietary cholesterol and experimental conditions on serum lipids in man. I, II, III. Am. J. Clin. Nutr. 32:2183 (1980).Google Scholar
  39. 39.
    P. Mistry, A. Nicoll, C. Niehaus, etal., Effects of dietary cholesterol on serum lipoproteins in man, Prot. Biol. Fluids, 25: 349 (1978).Google Scholar
  40. 40.
    R.W. Mahley, T.L. Innerarity, T.B. Bersot, etal., Alterations in human high density lipoproteins, with or without increased plasma-cholesterol, induced by diets high in cholesterol, Lancet ii: 807 (1978).Google Scholar
  41. 41.
    H.D. Trowell, A.T. Southgate, T.M.S. Wolever, etal., Dietary fibre redefined, Lancet i: 967 (1976).Google Scholar
  42. 42.
    D.P. Burkitt, A.R.P. Walker, and N.S. Painter, Dietary fiber and disease, J. Am. Med. Ass. 229:1068 (1974).Google Scholar
  43. 43.
    R.M. Kay and P.A. Judd, and A.S. Truswell, The effect of pectin on serum cholesterol, Am. J. Clin. Nutr. 31:562 (1978).Google Scholar
  44. 44.
    D.J.A. Jenkins, A.C. Newton, A.R. Leeds, etal., Effect of pectin, guar gum and wheat fiber on serum cholesterol, Lancet i: 116 (1975).Google Scholar
  45. 45.
    T.L. Raymond, W.E. Connor, D.S. Lin, etal., The interaction of dietary fibers and cholesterol upon the plasma lipids and lipoproteins, sterol balance, and bowel function in human subjects, J. Clin. Invest. 60: 1429 (1977).PubMedCrossRefGoogle Scholar
  46. 46.
    M.R. Malinow, P. McLaughlin, L. Papworth, etal., Effect of alfalfa saponins on intestinal cholesterol absorption in rats, Am. J. Clin. Nutr. 30:2061 (1972).Google Scholar
  47. 47.
    M.R. Malinow, P. McLaughlin, H.K. Naito, etal., Effect of alfalfa meal on shrinkage (regression) of atherosclerotic plaques during cholesterol feeding in monkeys, Atherosclerosis 30: 27 (1978).PubMedCrossRefGoogle Scholar
  48. 48.
    D.J.A. Jenkins, D. Reynolds, B. Slavin, etal., Dietary fiber and blood lipids: treatment of hypercholesterolaemia with guar gum, Am. J. Clin. Nutr. 33:575 (1980).Google Scholar
  49. 49.
    A.R. Mendeloff, Dietary fibre, Presented at the First Int. Symp. on Clinical Nutrition, London, July 1980.Google Scholar
  50. 50.
    M. Stasse-Wolthuis, H.F.F. Albers, J.G.C. van Jeveren, etal., Influence of dietary fiber from vegetables and fruits, bran or citrus pectin on serum lipids, fecal lipids, and colonic function, Am. J. Clin. Nutr. 33:1745 (1980).Google Scholar
  51. 51.
    A. Ignatowski, Uber die Wirkung der tierischen Eiweisses auf die Aorta und die parenchymatösen Organer der Kaninchen, Virchows Arch. 198: 248 (1909).CrossRefGoogle Scholar
  52. 52.
    L.H. Newburgh and S. Clarkson, The production of Atherosclerosis in rabbits by feeding diets rich in meat, Arch. Int. Med. 31: 653 (1923).CrossRefGoogle Scholar
  53. 53.
    S. Clarkson and L.H. Newburgh, The relation between Atherosclerosis and ingested cholesterol in rabbits, J. Exp. Med. 43: 592 (1926).CrossRefGoogle Scholar
  54. 54.
    M.W. Huff, R.M.G. Hamilton, and K.K. Carroll, Plasma cholesterol levels in rabbits fed low fat, cholesterol-free, semipurified diets: effects of dietary proteins, protein hydrolysates and amino acid mixtures, Atherosclerosis 28: 187 (1977).PubMedCrossRefGoogle Scholar
  55. 55.
    C.R. Sirtori, E. Agradi, F. Conti, etal., Soybean protein diet in the treatment of type II hyperlipoproteinaemia, Lancet i: 275 (1977).Google Scholar
  56. 56.
    C.R. Sirtori, G.C. Descovich, and G. Noseda, Textured soy protein and serum cholesterol, Lancet i: 149 (1980).Google Scholar
  57. 57.
    J. Van Raaj, M.B. Katan, and J.G.A.J. Hautvast, CaScin, soja protein and serum cholesterol, Lancet ii: 958 (1979).Google Scholar
  58. 58.
    C.R. Sirtori, E. Gatti, O. Mantero, etal., Clinical experience with the soybean protein diet in the treatment of hypercholesterolemia, Am. J. Clin. Nutr. 32:1645 (1979).Google Scholar
  59. 59.
    G.C. Descovich, C. Ceredi, A. Gaddi, etal., Multicenter study of soybean protein diet for outpatient hypercholes- terolaemic patients, Lancet ii: 709 (1980).Google Scholar
  60. 60.
    W.L. Holmes, G.B. Rubel, and S.S. Hood, Comparison of the effects of dietary meat versus dietary soybean protein on plasma lipids of hyperlipidemic individuals, Atherosclerosis 36: 379 (1980).CrossRefGoogle Scholar
  61. 61.
    C.R. Sirtori, G.C. Descovich and G. Noseda, The soybean protein diet does not lower plasma cholesterol?, Atherosclerosis, in press (1981).Google Scholar
  62. 62.
    R. Fumagalli, R. Paoletti and A. Howard, Hypocholesterolaemic effect of soya, Life Sci. 22: 947 (1978).PubMedCrossRefGoogle Scholar
  63. 63.
    D.M. Kim, K.T. Lee, J.M. Reiner, and W.A. Thomas, Effects of a soy protein product on serum and tissue cholesterol concentrations in swine fed high-fat, high cholesterol diets, Exp. Mol. Pathol. 29: 385 (1978).PubMedCrossRefGoogle Scholar
  64. 64.
    J.M. Potter and P.J. Nestel, Greater bile acid excretion with soybean than with cow milk in infants, Am. J. Clin. Nutr. 32:1645 (1976).Google Scholar
  65. 65.
    R. Fumagalli, L. Soleri, O. Mantero, etal., Cholesterol balance studies in type II hypercholesterolaemic patients treated with the soybean protein diet, Clin. Sci., submitted for publ.Google Scholar
  66. 66.
    J.H. Mendelson and N.K. Mello, Alcohol-induced hyperlipidemia and beta-lipoproteins, Science 180: 1372 (1973).PubMedCrossRefGoogle Scholar
  67. 67.
    L. Puglisi, V. Caruso, F. Conti, etal., Effect of hypolipidemic and hypoglycemic drugs on ethanol induced hypertriglyceridemia in rats, Pharmacol. Res. Comm. 9:71 (1977).Google Scholar
  68. 68.
    D.E. Wilson, P.H. Schreibman, A.C. Breston, and R.A. Arky, The enhancement of alimentary lipemia by ethanol in man, J. Lab. Clin. Med. 75:264 (1970).Google Scholar
  69. 69.
    W.P. Castelli, T. Gordon, M.C. Hjortland, etal., Alcohol and blood lipids. The cooperative lipoprotein phenotyping study, Lancet ii: 153 (1977).Google Scholar
  70. 70.
    G.J. Miller and N.E. Miller, Plasma high-density lipoprotein concentration and development of ischaemic heart-disease, Lancet i: 16 (1975).Google Scholar
  71. 71.
    K. Yano, G.G. Rhoads, and A. Kagan, Coffee, alcohol and risk of coronary death, among Japanese men living in Hawaii, N. Eng. J. Med. 297, 405 (1977).Google Scholar
  72. 72.
    A.S. St. Leger, A.L. Cochrane, and F. Moore, Factors associate ed with cardiac mortality in developed countries with particular reference to the consumption of wine, Lancet i: 1017 (1979).Google Scholar
  73. 73.
    P. Ducimetiere, J.L. Richard, F. Cambien, etal., Coronary heart disease in middle-age Frenchmen, Lancet, i: 1347 (1980).Google Scholar
  74. 74.
    P. Nilsson-Ehle, Alcohol induced alterations on lipoprotein lipase activity and plasma lipoproteins, in “Metabolic Effects of Alcohol”, P. Avogaro, Elsevier/ North Holland, Amsterdam, p. 175 (1979).Google Scholar
  75. 75.
    J.R. Patsch, A.M. Gotto Jr., T. Olivecrona, and S. Eisenberg, Formation of high density lipoprotein-like particles during lipolysis of very low density 2lipoproteins in vitro, Proc. Natl. Acad. Sci. USA 75:4519 (1978).Google Scholar
  76. 76.
    T.R. Dawber, W.B. Kannel, and T. Gordon, Coffee and cardiovascular disease: Observations from the Framingham study, N. Eng. J. Med. 291:871 (1974).Google Scholar
  77. 77.
    D. Robertson, J.L. Fröhlich, R.K. Carr, etal., Effects of caffeine on plasma renin activity, catecholamines and blood pressure, N. Eng. J. Med., 298:181 (1978).Google Scholar
  78. 78.
    S. Hayden, H.A. Tyroler, G. Heiss, etal., Coffee consumption and mortality, J. Am. Med. Ass., 138:1472 (1978).Google Scholar
  79. 79.
    N.E. Hag, J.G. Elliott, and P.A. Lachance, Effect of tea on serum cholesterol using a hypercholesterolemic rat model, Nutr. Rep. Int., 15: 89 (1977).Google Scholar
  80. 80.
    M.N. Callahan, M.N. Rohovsky, R.S. Robertson, and D.W. Yesair, The effect of coffee consumption on plasma lipids, lipoproteins, and the development of aortic Atherosclerosis in Rhesus monkeys fed an atherogenic diet, Am. J. Clin. Nutr. 32:834 (1979).Google Scholar
  81. 81.
    S. Heyden, G. Heiss, C. Manegold, etal., The combined effect of smoking and coffee drinking on LDL and HDL cholesterol. Circulation, 60: 22 (1979).Google Scholar
  82. 82.
    A cooperative trial in the prevention of ischaemic heart disease using Clofibrate, Brit. Heart J., 40: 1069 (1978).Google Scholar
  83. 83.
    W.H.O. Cooperative trial on primary prevention of ischaemic heart disease using Clofibrate to lower serum cholesterol: mortality follow-up, Lancet ii: 379 (1980).Google Scholar
  84. 84.
    E.A. Nikkila, J.K. Huttunen, and C. Ehnholm, Effect of Clofibrate on post-heparin plasma triglyceride lipase activities in patients with hypertrigliceridemia, Metabolism 26: 179 (1977).PubMedCrossRefGoogle Scholar
  85. 85.
    G. Klose, J. Behrendt, J. Vollmar, and H. Greten, Wirkung von Bezafibrate auf die Lipoprotein Lipase Aktivität und die Leber-Triglyceridhydrolase bei gesunden Versuschpersonen, in “Lipoproteine und Herzinfarkt”, H. Greten etal., G. Witzstrock Verlag, Baden-Baden, p. 185 (1979).Google Scholar
  86. 86.
    L.A. Carlson, A.G. Olsson, and D. Ballantyne, On the rise of low density and high density lipoproteins in response to the treatment of hypertriglyceridemia in type IV and V hyperlipoproteinemias, Atherosclerosis 26: 603 (1973).CrossRefGoogle Scholar
  87. 87.
    G. D’Atri, P. Gomarasca, E. Galimberti, etal., Clofibrate, Pirinixil (BR 931) and Wy-14,643 do not affect body cholesterol in Sprague-Dawley rats, Atherosclerosis 37: 475 (1980).Google Scholar
  88. 88.
    S.M. Grundy, E.H. Ahrens, G. Sälen, etal., Mechanism of action of Clofibrate on cholesterol Metabolism in patients with hyperlipidemia, J. Lipid Res. 13:531 (1972).Google Scholar
  89. 89.
    G. Schlierf, M. Chwat, E. Feuerborn, etal., Biliary and plasma lipids and lipid-lowering chemotherapy. Atherosclerosis 36: 323 (1980).CrossRefGoogle Scholar
  90. 90.
    T.A. Miettinen, J.K. Huttunen, C. Ehnholm, etal., Effect of long-term antihypertensive and hypolipidemic treatment on high density lipoprotein and apolipoproteins A-I and A-II, Atherosclerosis 36: 249 (1980).PubMedCrossRefGoogle Scholar
  91. 91.
    J.G. Brook, A. Lavy, M. Aviram, and M. Zinder, The concentration of high density lipoprotein in patients with type IV hyperlipoproteinemia and the effect of Clofibrate, Atherosclerosis 36: 461 (1980).PubMedCrossRefGoogle Scholar
  92. 92.
    The Coronary Drug Project: Clofibrate and niacin in coronary heart disease, J. Am. Med. Ass. 231:360 (1975).Google Scholar
  93. 93.
    J. Reddy, D.L. Azarnoff, and C.R. Sirtori, Hepatic peroxisome proliferation: induction by BR-931, a hypolipidemic analog of WY-14,643, Arch. Int. Pharmacodyn. 234: 4 (1978).PubMedGoogle Scholar
  94. 94.
    J. Reddy, D. Azarnoff and C. Hignite, Hypolipidemic hepaticperoxisome proliferators form a novel class of hepatocar-cinogens, Nature 283: 397 (1980).PubMedCrossRefGoogle Scholar
  95. 95.
    M. Hanefeld, Ch. Remmer, W. Leonhardt, etal., Effects of p-chlorophenoxy-isobutyric acid (CPIB) on the human liver, Atherosclerosis 36: 159 (1980).PubMedCrossRefGoogle Scholar
  96. 96.
    H. Ishii, N. Fukumori, S. Horie, and T. Suga, Effects of fat content in the diet on hepatic peroxisomes of the rat, Biochim. Biophys. Acta 617:1 (1980).Google Scholar
  97. 97.
    H. Ishii, N. Fukumori, S. Horie, and T. Suga, Effects of fat content in the diet on hepatic peroxisomes of the rat, Biochim. Biophys. Acta 617:1 (1980).Google Scholar
  98. 98.
    D.L. Azarnoff, J. Reddy, C. Hignite, and T. Fitzgerald, Structure activity relationships of Clofibrate like com-pounds on lipid Metabolism, in MProc. VI Int. Congress of Pharmacology, vol. 4, M. Vapaatalo, ed., Pergamon Press, Oxford, p. 137 (1976).Google Scholar
  99. 99.
    E.A. Nikkila and O. Pykalisto, Induction of adipose tissue lipoprotein lipase by nicotinic acid, Biochim. Biophys. Acta 152:421 (1968).Google Scholar
  100. 100.
    L.A. Carlson and L. Oro, Acute effect of a sustained release pyridyl carbinol preparation, ronicol retard, on plasma free fatty acids, Acta Med. Scand. 183:457 (1968).Google Scholar
  101. 101.
    T. Langer and R.T. Levy, The effect of nicotinic acid on the turnover of low density lipoproteins in type II hyperlipo-proteinemia, in “Metabolic effects of nicotinic acid and its derivatives”, K.F. Gey and L.A. Carlson, Hans Huber Publ., Bern, p. 641 (1971).Google Scholar
  102. 102.
    J. Shepherd, C.J. Packard, J.R. Patsch, etal., Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition, and of apolipoprotein A Metabolism. J. Clin. Invest. 63: 858 (1979).PubMedCrossRefGoogle Scholar
  103. 103.
    C.J. Packard, J.M. Stewart, J.L. Third, Effects of nicotinic acid therapy on high-density lipoprotein metaboslism in type II and type IV hyperlipoproteinemia, Biochim. Biophys. Acta 618:53 (1980).Google Scholar
  104. 104.
    H.Y.I. Mok and S.M. Grundy, Effects of nicotinic acid on biliary lipids in man, Gastroenterology 73: 1235 (Abs.) (1977).Google Scholar
  105. 105.
    B. Angelin, K. Einarsson, and B. Lleijd, Biliary lipid composition during treatment with different hypolipidaemic drugs, Eur. J. Clin. Invest. 9: 185 (1979).PubMedCrossRefGoogle Scholar
  106. 106.
    G. Baggio, G. Briani, R. Fellin etal., Effect of tiadenol on the concentration and composition of serum lipoproteins in familial hypercholesterolemia, Artery 5: 486 (1979).Google Scholar
  107. 107.
    J. Rouffy and J. Loeper, Effects hypolipidemiants du bis (hydroxy-2-ethylthio) 1.10 décane (LL 1558), Thérapie 27: 433 (1974).Google Scholar
  108. 108.
    E. Martin and G. Feldman, Etude hystologique et ultrastructural du foie chez le rat après administration subaigue d’n nouvel agent hypolipémiant, le bis (hydroxyethylthio) 1.10 décane, Pathol. Biol. XXII-II: 179 (1974).Google Scholar
  109. 109.
    D. Kritchevsky, S.A. Tepper, S.K. Czarnecki, etal., Influence of tiadenol, bis-(hydroxy-ethyltio) 1.10 decane, on cholesterol Metabolism in rats, Pharmacol. Res. Comm. 11:475 (1979).Google Scholar
  110. 110.
    G. Franceschini, A. Catapano, A. Poli, etal., Pharmacological studies on tiadenol in type IV patients: evidence for a mechanism of action different from other lipid lowering drugs, Atherosclerosis, submitted for pubi.Google Scholar
  111. 111.
    G. Schonfeld, F. Bell and D.H. Alpers, Intestinal apoproteins during fat absorption, J. Clin. Invest. 61: 1539 (1977).CrossRefGoogle Scholar
  112. 112.
    C.R. Sirtori, A. Catapano, G.C. Ghiselli, etal., Metformin: an antiatherosclerotic agent modifying very low density lipoproteins in rabbits, Atherosclerosis 26: 79 (1977).PubMedCrossRefGoogle Scholar
  113. 113.
    C.R. Sirtori, A. Catapano, G.C. Ghiselli, etal., Effects of metformin on lipoprotein composition in rabbits and man, Prot. Biol. Fluids 25: 379 (1978).Google Scholar
  114. 114.
    R.W. Stout, J.D. Brunzell, D. Porte Jr., and E.L. Bierman, Effect of phenformin on lipid transport in hypertriglyceridemia, Metabolism 23: 815 (1974).PubMedCrossRefGoogle Scholar
  115. 115.
    W. Lintz, W. Berger, W. Aenishaenslin etal., Butylbiguanide concentration in plasma, liver and intestine after intravenous and oral administration to man. Eur. J. Clin. Pharmacol. 7: 433 (1974).PubMedCrossRefGoogle Scholar
  116. 116.
    G. Weber, A. Catapano, G.C. Ghiselli and C.R. Sirtori, Experimental studies on the antiatherosclerotic effect of metformin, in “International Conference on Atherosclerosis”, L.A. Carlson etal., Eds., Raven Press, New York, p. 319 (1978).Google Scholar
  117. 117.
    R. Paoletti, R. Fumagalli, A. Poli, and C.R. Sirtori, Biochemical analysis of hypolipidemic versus anti-atherosclerotic drugs, Atherosclerosis Rev. 7: 213 (1980).Google Scholar
  118. 118.
    C.R. Sirtori, G. Franceschini, M. Sirtori, etal., Apoprotein changes following treatments with hypolipidemic drugs, in “Atherosclerosis V”, A.M. Gotto etal., eds., Springer Verlag, New York, p. 90 (1980).Google Scholar
  119. 119.
    G.C. Descovich, U. Montaguti, C. Ceredi, etal., Long-term treatment with metformin in a large cohort of hyperlipidemic patients, Artery 4: 348 (1978).Google Scholar
  120. 120.
    E. Tremoli, G.C. Ghiselli, P. Maderna, etal., Metformin reduces platelet hypersensitivity in hypercholesterolemic rabbits, Atherosclerosis, submitted for publ.Google Scholar
  121. 121.
    C.J. Glueck, S. Ford, D. Scheel, and P. Steiner, Colestipol and cholestyramine resin, J. Am. Med. Ass. 222:676–681Google Scholar
  122. 122.
    A.E. Dorr, K. Gundersen, J.C. Schneider Jr., etal., Colestipol hydrochloride inhypercholesterolemic patients. Effects on serum cholesterol and mortality, J. Chron. Pis. 31: 5 (1978).CrossRefGoogle Scholar
  123. 123.
    R.W. Wissler, D. Vesselinovitch, J. Borensztajn, and R. Hughes, Regression of severe Atherosclerosis in cholesty- ramine-treated Rhesus monkeys with or without a low-fat, low-cholesterol diet, Circulation 52 (suppl. II): 11–16 (1976).Google Scholar
  124. 124.
    R.G. De Palma, E.M. Bellon, S. Koletsky, and D.L. Schneider, Atherosclerotic plaque regression in Rhesus monkeys induced by bile acid sequestrant, Exp. Mol. Pathol. 31: 423 (1979).CrossRefGoogle Scholar
  125. 125.
    C.D. Moutafis, N.B. Myant, M. Mancini, and P. Oriente, Cholestyramine and nicotinic acid in the treatment of familial hyperbetalipoproteinemia in the homozygous form, Atherosclerosis 20, 105 (1971).Google Scholar
  126. 126.
    G.S. Boyd, A.M. Grimwade, and M.E. Lawson, Studies on microsomal cholesterol 7a-hydroxylase, Eur. J. Biochem. 37: 334 (1973).PubMedCrossRefGoogle Scholar
  127. 128.
    R. Adler, E. Margules, R. Motson, etal., Increased production of triglyceride-rich lipoproteins after partial biliary diversion in the Rhesus monkey, Metabolism 27: 607 (1978).PubMedCrossRefGoogle Scholar
  128. 129.
    B. Angelin, K. Einarsson, and B. Leijd, Effect of chenodeoxy-cholic acid on serum and biliary lipids in patients with hyperlipoproteinemias, Clin. Sci. 54: 451 (1978).Google Scholar
  129. 130.
    G. Sigurdsson, A. Nicoll, and B. Lewis, Conversion of very low density lipoprotein to low density lipoprotein. A metabolic study of apolipoprotein B kinetics in normal subjects, J. Clin. Invest. 56: 1481 (1975).PubMedCrossRefGoogle Scholar
  130. 131.
    A. Soutar, N.B. Myant, and G.R. Thompson, Simultaneous measurement of apolipoprotein B turnover in very-low and low-density lipoproteins in familial hypercholesterolemia, Atherosclerosis 28: 247 (1977).PubMedCrossRefGoogle Scholar
  131. 132.
    G.C. Ghiselli, M. Marinovich, and C.R. Sirtori, Apoprotein B turnover in normal rabbits: evidence for a dual biosyn- thetic and catabolic pool of apo B in low density lipoproteins, Artery, submitted for publication.Google Scholar
  132. 133.
    R.I. Levy and T. Langer, Hypolipidemic drugs and lipoprotein Metabolism, Adv. Exp. Med. Biol. 26: 155 (1972).PubMedGoogle Scholar
  133. 135.
    H.R. Slater, C.J. Packard, S. Bicker, and J. Shepherd, Effects of cholestyramine on receptor-mediated plasma clearance of human low density lipoproteins in the rabbit, J. Biol. Chem. 255: 10210 (1980).PubMedGoogle Scholar
  134. 136.
    J.L. Witztum, G. Schonfeld, S.W. Weidman, etal., Bile sequestrant therapy alters the compositions of low-density and high-density lipoproteins, Metabolism 28: 221 (1979).PubMedCrossRefGoogle Scholar
  135. 137.
    N. Tanaka, S. Sakaguchi, K. Oshige etal., Effect of chronic administration of propranolol on lipoprotein composition, Metabolism 25: 1071 (1976).PubMedCrossRefGoogle Scholar
  136. 138.
    R.P. Ames and P. Hill, Elevation of serum lipid levels during diuretic therapy of hypertension, Am. J. Med. 61: 748 (1976).Google Scholar
  137. 139.
    J. Shaw, J.D.F. England, K. Oshige, etal., Beta-blockers and plasma triglycerides, Brit. Med. J. i: 986 (1978).Google Scholar
  138. 140.
    P. Bielmann and G. Leduc, Effect of metaprolol and proprano lol on lipid Metabolism, Int. J. Clin. Pharmacol. Biopharm. 17: 378 (1979).Google Scholar
  139. 141.
    G. Noseda and C.R. Sirtori, Klinische Prufung von ”Tibric Acid“, einem neuem lipidsenkenden Stoff, Schweiz. Med. Wschr. 104:1917 (1974).Google Scholar
  140. 142.
    C.R. Sirtori, D.W. Shoeman, and D.L. Azarnoff, Dissociation of the metabolic and cardiovascular effects of the 3-ad-srenergic blocker practolol, Pharmacol. Res. Comm. 4:123 (1972).Google Scholar
  141. 143.
    C. Joos, H. Kewitz, and D. Reinholdt-Kourniati, Effects of diuretics on plasma lipoproteins in man, Eur. J. Clin. Pharmacol. 17: 251 (1980).PubMedCrossRefGoogle Scholar
  142. 144.
    P. Leren, P.O. Foss, A. Helgeland, etal., Effect of propranolol and prazosin on plasma lipids, Lancet ii: 4 (1980).Google Scholar
  143. 145.
    K. Ball and R. Turner, Smoking and the heart. The basis for action, Lancet ii: 822 (1974).Google Scholar
  144. 146.
    L.A. Carlson and B. Kolmodin-Hedman, Hyper-a-lipoproteinemia in men exposed to chlorinated hydrocarbon pesticides, Acta Med. Scand. 192:29 (1972).Google Scholar
  145. 147.
    L.A. Carlson and B. Kolmodin-Hedman, Decrease in a-lipoprotein cholesterol in men after cessation of exposure to chlorinated hydrocarbon pesticides, Acta Med. Scand. 201: 375 (1977).Google Scholar
  146. 148.
    E.A. Nikkila, M. Koste, C. Ehnholm, and J. Viikari, Elevation of high density lipoprotein in epileptic patients treated with phenytoin, Acta Med. Scand. 204:517 (1978).Google Scholar
  147. 149.
    A. Poli, G. Franceschini, L. Puglisi, and C.R. Sirtori, In creased total and high density lipoprotein cholesterol, with apolipoprotein changes resembling streptozotocin diabetes in tetrachlorodibenzodioxin (TCDD) treated rats, Biochem. Pharmacol. 29:835 (1980).Google Scholar
  148. 150.
    M.R. Juchau, J.A. Bond, and E.A. Benditt, Aryl 4-monoxygen-ase and cytochrome P-450 in the aorta: Possible role in atherogenesis, Proc. Natl. Acad. Sci. USA 73:3723 (1976).Google Scholar
  149. 151.
    J.A. Zack and R.R. Suskind, The mortality experience of workers exposed to tetrachlorodibenzodioxin in a trichloro- phenol process accident, J. Occup. Med. 22:11 (1980).Google Scholar
  150. 152.
    R.J. Garrison, W. Kannel, M. Feinleib, etal., Cigarette smoking and HDL cholesterol. The Framingham Offspring Study, Atherosclerosis 30: 17 (1978).CrossRefGoogle Scholar
  151. 153.
    R.S. Gardner, D.L. Topping, and P.A. Mayes, Immediate effects of carbon monoxide on the Metabolism of chylomicron remnants by perfused rat liver, Biochim. Biophys. Res. Comm. 82:526 (1978).Google Scholar

Copyright information

© Plenum Press, New York 1982

Authors and Affiliations

  • Cesare R. Sirtori
    • 1
  1. 1.Center E. Grossi Paoletti and Chemotherapy ChairUniversity of MilanMilanItaly

Personalised recommendations